🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06694051
Recruiting Not applicable

Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism

NCT06694051 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Eye Hospital
Phase
Not applicable
Started
2024-10-01
Last updated
2024-11-19

Condition(s) studied

Astigmatism

Investigational drug(s) / intervention(s)

marking

marking: axis marking

Study summary

Corneal refractive surgery is an effective way to correct refractive error. Modern corneal refractive surgery for the correction of myopia or hyperopia can achieve or close to the expected goal, but to eliminate astigmatism is always one of the major problems of corneal refractive surgery. The key point in the correction of astigmatism is that as a vector parameter, astigmatism has both magnitude and direction. The angle error may be caused by the rotation of the patient's head position and the involuntary rotation of eyes. Phototherapeutic keratectomy can precisely cut the corneal tissue, and is often used in clinic to remove corneal scars or repair corneal surface morphology. In this study, the excimer laser therapeutic keratectomy mode was used to achieve accurate marking of the axis of astigmatism by setting the treatment laser parameters. With the help of the static cyclotorsion of the eye, the precise treatment of astigmatism could realize.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * at least 18 years old Exclusion Criteria: * ocular disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tianjin Eye Hospital Tianjin Tianjin Municipality Recruiting

More Tianjin Eye Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06694051 on ClinicalTrials.gov ↗ ← All trials in China